KIHT collaborates with JBI to improve market access of healthcare technology

In order to improve market access of medical technology, Kalam Institute of Health Technology (KIHT) has got formally inducted as a Joanna Briggs Institute (JBI) for India for evidence synthesis and technology assessments. This development took place on October 15, 2018 which happens to be the birthday of Dr. A P J Abdul Kalam.

The structured approach of the JBI system is to generate evidence by carrying out bonafide systematic review and meta-analysis through engaging international groups of JBI. The process of developing transparent and evidence-based decision-making for health technologies would add value to the innovative product credibility.

The research arm of AMTZ, KIHT has collaborated with JBI as an affiliate as it is a premium research and development centre, under health and medical sciences at the University of Adelaide, South Australia. The Institute supports development of evidences to improve healthcare outcomes globally and implement such outcomes by seeking feasibility, appropriateness, meaning and effectiveness. JBI collaborates with around 70 entities across globe.

The affiliation group formed in collaboration with KIHT for JBI standards to the health technology landscape strengthens the health technology assessment (HTA) programme under KIHT. It also opens up avenues for government, academia as well as private partners in more validated health access avenues in the country, adding another feather to the growing recognition of the MedTech capital of the country acclaimed worldwide.

A Letter of Intent (LoI) has earlier been signed between BioCubaFarma, Biotechnology Industry Research Assistance Council (BIRAC) and KIHT with focus on exchange of technologies, products,  innovations, transfer of technologies and commercialization of innovative healthcare products of interest to both the countries.

BioCubaFarma is the Cuban organization of biotechnology and pharmaceutical industries which manages the country’s efforts towards manufacturing medicines, diagnostics and medical equipment. It also serves as a gateway for potential partners and investors interested in accessing the extensive biopharma resources Cuba has to offer.

KIHT is the premier institute of the country for promoting back end support to the growing medical technology and plays an active role in supporting activities related to research on critical components of health technologies, commercial exploitation of newer technologies, apart from being a front runner in providing regulatory and non-regulatory support for stakeholders in health technologies.